Reacción a "A study shows that changes in the gut microbiome can identify people at risk of developing Parkinson's disease"

The main problem with studies examining the association between the microbiota and specific diseases is that they typically lack a design suitable for understanding their clinical implications or determining whether the results are generalizable. This study, however, features an impeccable design (within the limitations of observational studies) in which it not only describes a healthy population and a diseased population (Parkinson’s patients), but also studies patients with a genetic variant that carries a high risk of developing the disease (somewhere between healthy and diseased individuals) using a large sample size. Consistently, they describe a subgroup of bacteria with predictive value for the development of the disease in its early stages and successfully validate it in independent cohorts from other populations. The metabolic functions of these bacteria allow us to explain—or at least generate plausible hypotheses—about how Parkinson’s disease begins in the gut rather than in the brain years before the characteristic neurological symptoms of Parkinson’s develop.

Intestinal symptoms, such as constipation, are characteristic of the gut in Parkinson’s patients, but the described intestinal dysbiosis appears to precede the development of the disease by years; therefore, the implications of the study are highly significant from the perspective of developing early intervention, whether in the form of dietary recommendations for high-risk individuals or the possibility of replacing damaged microbiota with healthy microbiota, such as through fecal microbiota transplantation.

The identified microbial signature must be validated prospectively, but this article undoubtedly presents very promising results.